WAYNE, PA., April 3 /CNW/ - PharmaStem Therapeutics, Inc. announced today
that the United States Patent and Trademark Office has confirmed all the
claims in its pioneering patents regarding umbilical cord blood stem cells.
The Patent Office had previously granted third party requests to reexamine
U.S. Patent Nos. 5,004,681, 5,192,553, 6,461,645 and 6,569,427, and has now
concluded, after reexamination, that all of the claims are valid.
"Considering the pioneering research of our inventors which eventually
led to the creation of the private and public cord blood banking industry, I
was always confident that the Patent Office would confirm the validity of our
patents and I am gratified that all three senior patent examiners involved in
the reexamination reached the same conclusion," said Nicholas Didier, CEO and
President of PharmaStem. "It is important for our licensees - of which there
are over 20 - to know that the patents they have licensed are valid, and can
Although the majority of private cord blood banks are licensed under
PharmaStem's patent portfolio, ViaCord (VIAC), Cryo-Cell (CCEL), CBR Systems
and CorCell do not have a license to practice the inventions claimed in
PharmaStem is the successor to Biocyte Corporation, and the pioneer in
the development of umbilical cord blood preservation and its therapeutic use.
Umbilical cord and placental blood are rich in stem cells that can
reconstitute human blood and immune systems. The Company provided the roadmap
for the creation of today's rapidly growing field of cord blood storage for
To learn more about PharmaStem Therapeutics, its patent portfolio and its
licensed cord blood banks, please visit www.pharmastem.com.
For further information:
For further information: PharmaStem Therapeutics, Inc. Nicholas Didier,
914-833-9227, extension 8005 President & CEO email@example.com